Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Dorothee Reynaud"'
Autor:
D Waldenberger, John R. Penrod, Clarisse Audigier-Valette, Sylvia Gütz, Martin Sebastian, Adrien Dixmier, Christian Schumann, Khalid Lakhdari, Rosalyn A. Juergens, Didier Debieuvre, P. Bombaron, Nicolas Benoit, Jean-Bernard Auliac, Ariadna Juarez-Garcia, Catherine Labbé, Victoria Allan, Christophe Raspaud, Bernard Asselain, Dorothee Reynaud, Andreas Gröschel, Fabrice Barlesi, Maurice Pérol, Filippa Pettersson, Charles A. Butts, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 157:40-47
Objectives Immune checkpoint inhibitors have become the standard of care for metastatic non–small-cell lung cancer (NSCLC) progressing during or after platinum-based chemotherapy. Real-world clinical practice tends to represent more diverse patient
Autor:
Pauline Lamoureux, Denis Moro-Sibilot, Thomas Egenod, P. Bombaron, Melinda Daumont, Audrey Rabeau, Adrien Dixmier, Christophe Raspaud, Nicolas Benoit, Didier Debieuvre, N. Ozan, Juliette Dumanoir, Bernard Asselain, Virginie Westeel, C. Calvet, Clarisse Audigier-Valette, Dorothee Reynaud, Victoria Allan, Fabrice Barlesi, François-Emery Cotté, Maurice Pérol, Jean-Bernard Auliac, Jérôme Fayette, Jean-Luc Labourey, Myriam Locatelli Sanchez
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and
Autor:
Victoria Allan, C. Raspaud, Fabrice Barlesi, Jean-Bernard Auliac, Maurice Pérol, J. Dumanoir, Adrien Dixmier, Dorothee Reynaud, Bernard Asselain, B. Nicolas, D. Moro-Sibilot, C. Calvet, Clarisse Audigier-Valette, P. Bombaron, Didier Debieuvre, F-E. Cotte
Publikováno v:
Annals of Oncology. 32:S1026
Autor:
Victoria Allan, F-E. Cotte, Adrien Dixmier, P. Bombaron, Bernard Asselain, Didier Debieuvre, D. Moro-Sibilot, N. Benoit, Clarisse Audigier-Valette, C. Raspaud, J. Dumanoir, Jean-Bernard Auliac, C. Calvet, N. Ozan, Fabrice Barlesi, Maurice Pérol, Dorothee Reynaud
Publikováno v:
Annals of Oncology. 31:S854-S855
Autor:
Adrien Dixmier, Denis Moro-Sibilot, Andreas Gröschel, Fabrice Barlesi, Sylvia Gutz, Maurice Pérol, Christian Schumann, John R. Penrod, Didier Debieuvre, Charles A. Butts, Dorothee Reynaud, D Waldenberger, Khalid Lakhdari, Filippa Pettersson, Martin Sebastian, Catherine Labbé, Clarisse Audigier-Valette, Victoria Allan, Rosalyn A. Juergens, Ariadna Juarez-Garcia
Publikováno v:
Journal of Clinical Oncology. 38:e21714-e21714
e21714 Background: Data from clinical studies demonstrate a long-term survival benefit of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC) patients with overall survival (OS) at two-years of 27%, however real-world data are
Autor:
Jean-Baptiste Assié, Christos Chouaïd, Hilario Nunes, Dorothée Reynaud, Anne-Françoise Gaudin, Valentine Grumberg, Ronan Jolivel, Baptiste Jouaneton, François-Emery Cotté, Boris Duchemann
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC) have pre-existing interstitial lung disease (ILD). These patients are usually excluded from immunotherapy clinical trials. Consequently, knowledge on outcomes followi
Externí odkaz:
https://doaj.org/article/aaeb77ceaeb54391980a9b65f9f243ac
Autor:
Fabrice Barlesi, Adrien Dixmier, Didier Debieuvre, Christophe Raspaud, Jean-Bernard Auliac, Nicolas Benoit, Pierre Bombaron, Denis Moro-Sibilot, Clarisse Audigier-Valette, Bernard Asselain, Thomas Egenod, Audrey Rabeau, Jérôme Fayette, Myriam Locatelli Sanchez, Jean-Luc Labourey, Virginie Westeel, Pauline Lamoureux, François-Emery Cotte, Victoria Allan, Melinda Daumont, Juliette Dumanoir, Dorothée Reynaud, Christophe Yannick Calvet, Nicolas Ozan, Maurice Pérol
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and
Externí odkaz:
https://doaj.org/article/213acd05a7a34a719db64a6b6903acd4